Bengi Ruken Yavuz

The paper identifies recurrent signaling pathways in breast cancer using single-cell data and suggests drug combinations targeting these pathways.

The paper uses molecular dynamics simulations to show that double mutations in PI3K variants lead to more active conformations and drug-targetable cryptic pockets, suggesting a conformational selection strategy for drug development.

The paper identifies key molecular pathways and proteins associated with melanoma brain metastasis through genomic analysis and suggests therapeutic strategies targeting these pathways.

This paper develops a signaling-based method to identify optimal protein combinations for anticancer drug therapy, validated using patient-derived data and xenografts.

The paper identifies co-occurring mutation pairs in cancer genomes that are associated with metastasis and provides a tool for predicting metastatic potential.

This study compares neurodevelopmental disorders and cancer, finding shared pathways but differing in signaling strength and outcomes.

The paper identifies latent driver double mutations in pan-cancer data and links them to clinical outcomes and drug response.